Wishing Mr. McDavid Stilwell greater responsibilities and exciting challenges in this impressive new chapter!
In a pivotal leadership move, CPTx, a pioneering biotech firm based in Germany, has named McDavid Stilwell as its new Chief Financial Officer (CFO). Stilwell steps into this strategic role to help accelerate the company’s leading innovations toward clinical trials and commercial success.
As CPTx continues to evolve its transformative pipeline, including in vivo CAR-T therapies for blood cancers and autoimmune conditions, and a self-delivering gene carrier platform, Stilwell will oversee critical aspects of financial stewardship, investor engagement, and business growth strategies.
The seasoned financial leader brings with him over 25 years of extensive experience in finance, corporate development, investor relations, and strategic communications within the biopharma landscape. His leadership résumé features prominent roles such as CFO at Coherus Biosciences, and key executive positions at Sangamo and Orexigen, where he played instrumental roles in driving financial performance and strategic direction.
Hendrik Dietz, CEO of CPTx, shared his confidence in the appointment:
“With his [Stilwell’s] deep biopharma finance, corporate strategy and investor relations experience, he boosts our executive team capabilities as we advance development of our lead programmes toward clinical development and potential partnerships.”
With his sights set on helping the company revolutionise genetic medicine, Stilwell expressed:
“I am excited to help lead the CPTx team to apply their expertise in single-stranded DNA technology to develop in vivo genetic medicines that overcome delivery and access challenges of current cell and gene therapies.”
Stilwell’s appointment marks a defining moment in CPTx’s growth journey—bringing together cutting-edge science and a strengthened financial foundation to navigate the complexities of biotech commercialisation. His leadership is expected to play a vital role in unlocking new partnerships, scaling innovation, and realising the company’s mission of reshaping how genetic therapies are delivered and accessed worldwide.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
